Conference Coverage

Medical treatment of perianal fistulae often warranted, despite limited evidence


 

EXPERT ANALYSIS FROM DIGESTIVE DISEASES: NEW ADVANCES

– Perianal fistulae are a common and difficult-to-treat complication of Crohn’s disease that may often require medical therapy, though not all treatment options have robust data supporting their use in this setting, according to Mark T. Osterman, MD.

“Most studies done on fistulae actually didn’t have that as the primary endpoint – it was a secondary endpoint, so they weren’t really designed to look at fistulae, specifically,” said Dr. Osterman, associate professor of medicine in the division of gastroenterology at the University of Pennsylvania in Philadelphia.

Dr. Osterman shared his own approach to medical treatment of perianal fistulae in a presentation he gave at Digestive Diseases: New Advances, jointly provided by Rutgers and Global Academy for Medical Education.

For simple perianal fistula with no rectal inflammation, a fistulotomy is reasonable, but medical treatment may be preferable, Dr. Osterman said.

“I always favor medical therapy because it attacks the root of the problem, which is the immune system,” he explained.

Helpful treatments in this scenario include antibiotics, along with anti–tumor necrosis factor therapy with or without immunomodulators, he said.

Antibiotic use in this setting is based on uncontrolled data, and efficacy is modest at best, according to Dr. Osterman, who noted that the treatments may reduce fistula drainage but likely do not heal fistulae.

The most commonly used antibiotics are metronidazole and ciprofloxacin given for up to 2-4 months, he added.

Pages

Recommended Reading

MDedge Daily News: Why the barber’s chair can help hypertension
MDedge Family Medicine
Do not miss cannabis use in gastroparesis patients
MDedge Family Medicine
Abdominal pain with high transaminases
MDedge Family Medicine
DPP-4 inhibitors increase IBD risk in diabetes
MDedge Family Medicine
H. pylori eradication cuts new gastric cancers by half
MDedge Family Medicine
MDedge Daily News: Avoid warfarin’s polypharmacy perils
MDedge Family Medicine
Maternal biologic therapy does not affect infant vaccine responses
MDedge Family Medicine
FDA approves certolizumab label update for pregnancy, breastfeeding
MDedge Family Medicine
MDedge Daily News: Treating H. pylori slashed new gastric cancers
MDedge Family Medicine
VIDEO: It is an exciting time in obesity treatment
MDedge Family Medicine